POsition of Leads in Advanced heaRt Failure: the POLAR Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to determine if lead positioning in the lateral wall of the left ventricle in patients meeting criteria for cardiac resynchronization therapy plays a role in determining myocardial function and affects the severity of mitral regurgitation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Intraventricular Electrical Activation in Resynchronization Therapy

NCT01270646

Heart Failure Cardiomyopathy, Dilated Coronary Disease

COMPLETED PHASE2

Mechanisms of Right Ventricular Adaptation in Patients With Heart Failure With Preserved Ejection Fraction

NCT04154657

Heart Failure, Diastolic

UNKNOWN NA

Significance of Impedance Cardiography and Early Repolarization Pattern in ECG in Congestive Heart Failure

NCT05480345

Congestive Heart Failure Chronic Heart Failure Right Ventricular Failure +1 more

COMPLETED NA

Guided Placement of CRT-Leads

NCT00764075

Heart Failure

COMPLETED NA

HeartGuide: Preliminary Study

NCT05490303

Cardiac Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 6 month, multi-centered, blinded, randomized study. Approximately 60 patients will join this study. Two groups, based on lead position, will be studied with thirty (30) patients randomized into each group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Resynchronization Therapy Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Postero-lateral

Left ventricular lateral wall lead position

Group Type ACTIVE_COMPARATOR

Postero-lateral

Intervention Type PROCEDURE

A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.

Antero-lateral

Left ventricular lateral wall lead position

Group Type ACTIVE_COMPARATOR

Antero-Lateral

Intervention Type PROCEDURE

A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Postero-lateral

A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.

Intervention Type PROCEDURE

Antero-Lateral

A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject meets the general indications for an implantable cardioverter defibrillator (ICD) with LV systolic function ≤ 35% as defined by echocardiography.
* Subject has moderate or severe heart failure, defined as NYHA Class III-IV for at least 90 days prior to enrollment.
* Subject has optimal pharmacological heart failure therapy for at least 30 days prior to enrollment.
* Subject has a 12-lead electrocardiogram (ECG) obtained no more than 90 days prior to enrollment documenting a sinus rate \> 50 bpm and PR interval \< 320 ms measured from any two leads.
* 12 lead ECG with left bundle brunch block morphology and a QRS duration of at least 120 msec.
* Subject has creatinine \< 2.5 mg/dL obtained no more than 30 days prior to enrollment.
* Subject has left ventricular ejection fraction \< 35% by echocardiogram no more than 1 year prior to enrollment.
* Subject is willing and capable of undergoing a device implant and participating in all testing associated with this clinical investigation.
* Subject has a life expectancy of more than 180 days, per physician discretion.
* Subject is age 18 or above, or of legal age to give informed consent specific to state and national law.

Exclusion Criteria

* Subject has right bundle branch block morphology on a 12-lead ECG obtained no more than 90 days prior to enrollment.
* Subject had previous cardiac resynchronization therapy, a previous coronary venous lead, or meets the general indications for anti-bradycardia pacing defined as ventricular pacing \> 40% by pacemaker interrogation.
* Subject has a neuromuscular, orthopedic, or other non-cardiac condition that prevents normal, unsupported walking.
* Subject has an atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention) or persistent (i.e., can be terminated with medical intervention, but does not terminate spontaneously) within 30 days prior to enrollment.
* Subject currently requires dialysis.
* Subject has severe chronic obstructive pulmonary disease (COPD), defined as FEV1/FVC \< 60%, or as defined by a physician.
* Subject has had a myocardial infarction within 30 days prior to enrollment or coronary artery disease (CAD) in which surgical or percutaneous correction was performed within 30 days prior to enrollment.
* Subject has hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis).
* Subject is on IV inotropic agents.
* Subject has any mitral valve prosthesis, or a mechanical aortic or tricuspid prosthesis
* Subject is enrolled in any concurrent study, without Medtronic written approval, which may confound the results of this study.
* Subject is pregnant or planning to get pregnant.
* Subject requires oxygen for medical reasons other than CHF.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No